In a research report that was published on Tuesday, analysts at Exane BNP Paribas moved Bayer Aktiengesellschaft (OTCMKTS: BAYRY) from having a “neutral” rating to having an “outperform” recommendation. This information was obtained from The Fly. The Bayer Aktiengesellschaft was the subject of this article. Bayry has been the subject of various articles and books published over the years. In research published on Tuesday, August 16th, Deutsche Bank Aktiengesellschaft boosted their price objective for Bayer Aktiengesellschaft and suggested “buying” shares of the company. The pricing goal was increased from €75.00 (equivalent to US$76.53) to €79.00 (equivalent to US$80.61). In a research report that was released on July 20th, Morgan Stanley stated that they have assigned an “overweight” rating to Bayer Aktiengesellschaft and that they have increased their price objective for the company from €83.00 ($84.69) to €85.00 ($86.73).
Both of these developments were announced by Bayer Aktiengesellschaft. In a report that was released on May 11th, Barclays assigned Bayer Aktiengesellschaft an “overweight” rating and increased their price objective for the firm from €85.00 ($86.73) to €90.00 ($91.84). In a report released on Thursday, May 19th, UBS Group gave the firm a “buy” rating. In a statement, it increased its price objective for Bayer Aktiengesellschaft from €90.00 ($91.84) to €96.00 ($97.96). Both cases made these two decisions with the corporation’s stock in mind. Ten research analysts have given the stock a buy rating. However, only one research analyst has given the stock a hold recommendation. According to the information that Bloomberg supplied, the current average rating for the company is “Moderate Buy,” and the price it is forecast to reach is $87.50. Additionally, the price at which it is expected to reach is anticipated to be $87.50.
The first transaction involving shares of BAYRY took place on Tuesday for $12.79. The price-to-earnings ratio for the company is 10.40, the price-to-growth ratio is 1.15, and the beta value is 1.08. The total value of the corporation, as measured by its market capitalization, is $50.26 billion. Currently, the debt-to-equity ratio stands at 0.97, the quick ratio stands at 0.88, and the current balance stands at 1.23. The company’s simple moving average for the past fifty days is $14.30, and the company’s simple moving average over the past two hundred days is $15.73. In the field of life sciences, Bayer Aktiengesellschaft, along with its numerous subsidiaries and affiliates, is a prominent player on a worldwide scale.
The corporation explicitly emphasizes crop science, consumer health, and medicine as its three primary areas of commercial focus. The pharmaceuticals sector is mainly responsible for the sale of prescription items for cardiology and women’s health care, in addition to specialist cancer, hematology, and ophthalmology drugs, diagnostic imaging equipment, contrast agents, and cell and gene therapy products. Cell and gene therapy are just two of the many additional medical services that may be found in this section.